Oral Azole Antifungal for Allergic Bronchopulmonary Aspergillosis
Itraconazole is the recommended first-line oral azole antifungal for ABPA, dosed at 200 mg twice daily (400 mg/day total) for 4 months, with mandatory therapeutic drug monitoring to maintain trough levels ≥0.5 mg/L. 1
First-Line Azole Selection
The 2024 ISHAM-ABPA Working Group guidelines explicitly recommend itraconazole as the preferred oral azole for initial ABPA therapy, based on considerable clinical experience and a favorable safety profile compared to other azoles 1. While voriconazole demonstrates similar efficacy to glucocorticoids, it should not be used first-line due to:
- Poorer patient tolerance
- Dose-dependent reduction in plasma concentrations when combined with prednisolone (a common co-therapy) 1
- Higher risk of adverse effects
Voriconazole, posaconazole, and isavuconazole are reserved for second-line use only when there are contraindications to glucocorticoids AND intolerance, failure, or resistance to itraconazole 1.
Dosing Protocol
Itraconazole Dosing
- Standard dose: 200 mg orally twice daily (total 400 mg/day)
- Duration: 4 months for acute ABPA 1
- Target trough level: ≥0.5 mg/L (some experts target ≥1 mg/L for better outcomes) 1
Alternative Azoles (Second-Line Only)
Therapeutic Drug Monitoring Requirements
TDM is mandatory for itraconazole due to significant bioavailability variations between formulations and frequent drug-drug interactions 1. The monitoring schedule should be:
- Initial assessment: 2 weeks after starting therapy
- Follow-up: At 3 months
- Additional monitoring: During any clinical worsening 1
Patients who experienced ABPA relapses in clinical studies had significantly lower itraconazole trough levels during the first 3 months of treatment, emphasizing the importance of early TDM 2.
Critical Drug Interactions
Itraconazole increases methylprednisolone plasma levels (but not prednisolone), creating higher risk of exogenous Cushing's syndrome and adrenal insufficiency when these agents are combined 1. This interaction also occurs with inhaled corticosteroids (budesonide, fluticasone) 1.
Rifampicin renders itraconazole levels undetectable and should be avoided 1.
Proton pump inhibitors and antacids do not affect itraconazole serum levels 1.
Monitoring Treatment Response
Assess response at 8-12 weeks using:
- Clinical symptoms (≥50% improvement on Likert scale or VAS)
- Chest radiographs (major improvement)
- Serum total IgE (≥20% reduction) 1
Monitor liver function tests in all patients receiving oral azoles 1.
When to Use Itraconazole vs. Glucocorticoids
The guidelines recommend either oral prednisolone OR oral itraconazole as first-line monotherapy for acute ABPA 1. The choice depends on:
Choose itraconazole when:
- Glucocorticoids are contraindicated (absolute indication) 1
- Patient has diabetes, osteoporosis, or other glucocorticoid-related risk factors
- Slower trajectory to improvement is acceptable (itraconazole has better safety profile but slower onset than steroids) 1
Combination therapy (itraconazole + prednisolone) is NOT recommended as first-line treatment, as a 2024 RCT of 191 patients showed no significant reduction in ABPA exacerbations compared to prednisolone alone, with higher adverse events 1. However, a short course of glucocorticoids (<2 weeks) may be added initially to itraconazole for symptom control 1.
Common Pitfalls to Avoid
- Do not use voriconazole first-line despite its proven efficacy—reserve it for itraconazole failures
- Do not skip TDM—subtherapeutic levels are associated with treatment failure and relapses
- Avoid methylprednisolone if combining with itraconazole—use prednisolone instead
- Do not treat asymptomatic ABPA with systemic antifungals unless there is poor asthma control or recurrent exacerbations 1
- Do not use high-dose inhaled corticosteroids alone as primary ABPA therapy—they are ineffective 1